

Saar Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1411641/publications.pdf>

Version: 2024-02-01

55
papers

5,376
citations

257450

24
h-index

214800

47
g-index

56
all docs

56
docs citations

56
times ranked

6652
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques. <i>Molecular Therapy</i> , 2022, 30, 209-222.	8.2	17
2	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	7.0	17
3	Macrophage-Based Approaches for Cancer Immunotherapy. <i>Cancer Research</i> , 2021, 81, 1201-1208.	0.9	327
4	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. <i>JAMA Internal Medicine</i> , 2021, 181, 195.	5.1	168
5	DARTs point the way forward in AML. <i>Blood</i> , 2021, 137, 720-721.	1.4	1
6	CAR-T cell persistence in the treatment of leukemia and lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2587-2599.	1.3	13
7	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. <i>Nature Medicine</i> , 2021, 27, 842-850.	30.7	88
8	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e246-e265.	3.8	27
9	Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.20.01739.	1.6	10
10	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	5.2	23
11	Longitudinal Large-Scale Semiquantitative Proteomic Data Stability Across Multiple Instrument Platforms. <i>Journal of Proteome Research</i> , 2021, 20, 5203-5211.	3.7	1
12	Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 783305.	4.8	73
13	Anti-FLT3 CAR T Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1703-1703.	1.4	1
14	Antigen Glycosylation Is a Central Regulator of CAR T Cell Efficacy. <i>Blood</i> , 2021, 138, 1721-1721.	1.4	2
15	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 795-795.	1.4	7
16	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-422.	1.6	162
17	Advances in chimeric antigen receptor T cells. <i>Current Opinion in Hematology</i> , 2020, 27, 368-377.	2.5	24
18	Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship. <i>Leukemia and Lymphoma</i> , 2020, 61, 3035-3037.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Human chimeric antigen receptor macrophages for cancer immunotherapy. <i>Nature Biotechnology</i> , 2020, 38, 947-953.	17.5	692
20	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. <i>Cancer Discovery</i> , 2020, 10, 552-567.	9.4	184
21	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2862-2871.	1.6	102
22	Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. <i>Blood</i> , 2020, 136, 30-30.	1.4	2
23	CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 697.	2.8	129
24	Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?. <i>Haematologica</i> , 2019, 104, 1302-1308.	3.5	62
25	Bispecific Antibodies in the Treatment of Hematologic Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 781-791.	4.7	52
26	Will CAR T cell therapy have a role in AML? Promises and pitfalls. <i>Seminars in Hematology</i> , 2019, 56, 155-163.	3.4	45
27	Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse. <i>Leukemia and Lymphoma</i> , 2018, 59, 1539-1553.	1.3	31
28	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. <i>Blood Advances</i> , 2018, 2, 575-585.	5.2	7
29	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. <i>Cell</i> , 2018, 173, 1439-1453.e19.	28.9	323
30	Novel Approaches to Acute Myeloid Leukemia Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 5502-5515.	7.0	56
31	Improved surfaceome coverage with a label-free nonaffinity-purified workflow. <i>Proteomics</i> , 2017, 17, 1600344.	2.2	9
32	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2395-2407.	1.4	148
33	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. <i>Cancer Discovery</i> , 2017, 7, 1154-1167.	9.4	149
34	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 235-246.	2.0	76
35	CAR T cells engage in anticancer martial arts. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1
36	Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	0

#	ARTICLE	IF	CITATIONS
37	Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 318-325.	2.3	2
38	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016, 127, 1117-1127.	1.4	381
39	Chimeric antigen receptor T cell therapy in AML: How close are we?. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 329-333.	1.7	22
40	Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. <i>American Journal of Hematology</i> , 2016, 91, 426-429.	4.1	3
41	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 2684-2696.	7.0	157
42	Poster child: Ready for a close-up. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
43	Teaching an old antibody new tricks. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
44	Losing inhibitions: Expect the unexpected. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
45	One step closer to viral eradication in HIV. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
46	Everything you splice can and will be used against you. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
47	An apple a day may not keep the doctor away, if you have AML. <i>Science Translational Medicine</i> , 2016, 8, .	12.4	0
48	The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse. <i>Clinical Cancer Research</i> , 2015, 21, 1981-1983.	7.0	2
49	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015, 5, 1282-1295.	9.4	997
50	Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. <i>Immunological Reviews</i> , 2015, 263, 68-89.	6.0	290
51	CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 37-49.	3.1	20
52	Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies. <i>Cancer Research</i> , 2014, 74, 6383-6389.	0.9	38
53	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. <i>Blood</i> , 2014, 123, 2343-2354.	1.4	396
54	T cell-based gene therapy of cancer. <i>Translational Research</i> , 2013, 161, 365-379.	5.0	18

#	ARTICLE	IF	CITATIONS
55	Reduced-Intensity Hematopoietic Stem Cell Transplants for Malignancies: Harnessing the Graft-Versus-Tumor Effect. Annual Review of Medicine, 2013, 64, 101-117.	12.2	20